112 related articles for article (PubMed ID: 36089245)
1. Tumor suppressor role of RBM22 in prostate cancer acting as a dual-factor regulating alternative splicing and transcription of key oncogenic genes.
Jiménez-Vacas JM; Montero-Hidalgo AJ; Gómez-Gómez E; Sáez-Martínez P; Fuentes-Fayos AC; Closa A; González-Serrano T; Martínez-López A; Sánchez-Sánchez R; López-Casas PP; Sarmento-Cabral A; Olmos D; Eyras E; Castaño JP; Gahete MD; Luque RM
Transl Res; 2023 Mar; 253():68-79. PubMed ID: 36089245
[TBL] [Abstract][Full Text] [Related]
2. Dysregulation of the splicing machinery is directly associated to aggressiveness of prostate cancer.
Jiménez-Vacas JM; Herrero-Aguayo V; Montero-Hidalgo AJ; Gómez-Gómez E; Fuentes-Fayos AC; León-González AJ; Sáez-Martínez P; Alors-Pérez E; Pedraza-Arévalo S; González-Serrano T; Reyes O; Martínez-López A; Sánchez-Sánchez R; Ventura S; Yubero-Serrano EM; Requena-Tapia MJ; Castaño JP; Gahete MD; Luque RM
EBioMedicine; 2020 Jan; 51():102547. PubMed ID: 31902674
[TBL] [Abstract][Full Text] [Related]
3. Splicing machinery dysregulation drives glioblastoma development/aggressiveness: oncogenic role of SRSF3.
Fuentes-Fayos AC; Vázquez-Borrego MC; Jiménez-Vacas JM; Bejarano L; Pedraza-Arévalo S; L-López F; Blanco-Acevedo C; Sánchez-Sánchez R; Reyes O; Ventura S; Solivera J; Breunig JJ; Blasco MA; Gahete MD; Castaño JP; Luque RM
Brain; 2020 Dec; 143(11):3273-3293. PubMed ID: 33141183
[TBL] [Abstract][Full Text] [Related]
4. Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer.
Jiménez-Vacas JM; Herrero-Aguayo V; Gómez-Gómez E; León-González AJ; Sáez-Martínez P; Alors-Pérez E; Fuentes-Fayos AC; Martínez-López A; Sánchez-Sánchez R; González-Serrano T; López-Ruiz DJ; Requena-Tapia MJ; Castaño JP; Gahete MD; Luque RM
Transl Res; 2019 Oct; 212():89-103. PubMed ID: 31344348
[TBL] [Abstract][Full Text] [Related]
5. The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressiveness.
Hormaechea-Agulla D; Gahete MD; Jiménez-Vacas JM; Gómez-Gómez E; Ibáñez-Costa A; L-López F; Rivero-Cortés E; Sarmento-Cabral A; Valero-Rosa J; Carrasco-Valiente J; Sánchez-Sánchez R; Ortega-Salas R; Moreno MM; Tsomaia N; Swanson SM; Culler MD; Requena MJ; Castaño JP; Luque RM
Mol Cancer; 2017 Aug; 16(1):146. PubMed ID: 28851363
[TBL] [Abstract][Full Text] [Related]
6. Alternative splicing of NF-YA promotes prostate cancer aggressiveness and represents a new molecular marker for clinical stratification of patients.
Belluti S; Semeghini V; Rigillo G; Ronzio M; Benati D; Torricelli F; Reggiani Bonetti L; Carnevale G; Grisendi G; Ciarrocchi A; Dominici M; Recchia A; Dolfini D; Imbriano C
J Exp Clin Cancer Res; 2021 Nov; 40(1):362. PubMed ID: 34782004
[TBL] [Abstract][Full Text] [Related]
7. RBM22, a Key Player of Pre-mRNA Splicing and Gene Expression Regulation, Is Altered in Cancer.
Soubise B; Jiang Y; Douet-Guilbert N; Troadec MB
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158909
[TBL] [Abstract][Full Text] [Related]
8. The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cancer.
Hormaechea-Agulla D; Jiménez-Vacas JM; Gómez-Gómez E; L-López F; Carrasco-Valiente J; Valero-Rosa J; Moreno MM; Sánchez-Sánchez R; Ortega-Salas R; Gracia-Navarro F; Culler MD; Ibáñez-Costa A; Gahete MD; Requena MJ; Castaño JP; Luque RM
FASEB J; 2017 Nov; 31(11):4682-4696. PubMed ID: 28705809
[TBL] [Abstract][Full Text] [Related]
9. Intron retention is a hallmark and spliceosome represents a therapeutic vulnerability in aggressive prostate cancer.
Zhang D; Hu Q; Liu X; Ji Y; Chao HP; Liu Y; Tracz A; Kirk J; Buonamici S; Zhu P; Wang J; Liu S; Tang DG
Nat Commun; 2020 Apr; 11(1):2089. PubMed ID: 32350277
[TBL] [Abstract][Full Text] [Related]
10. Lysine Demethylase 6B Regulates Prostate Cancer Cell Proliferation by Controlling c-MYC Expression.
Yıldırım-Buharalıoğlu G
Mol Pharmacol; 2022 Feb; 101(2):106-119. PubMed ID: 34862309
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin, Cortistatin and Their Receptors Exert Antitumor Actions in Androgen-Independent Prostate Cancer Cells: Critical Role of Endogenous Cortistatin.
Sáez-Martínez P; Porcel-Pastrana F; Pérez-Gómez JM; Pedraza-Arévalo S; Gómez-Gómez E; Jiménez-Vacas JM; Gahete MD; Luque RM
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361790
[TBL] [Abstract][Full Text] [Related]
12. miR-221-5p regulates proliferation and migration in human prostate cancer cells and reduces tumor growth in vivo.
Kiener M; Chen L; Krebs M; Grosjean J; Klima I; Kalogirou C; Riedmiller H; Kneitz B; Thalmann GN; Snaar-Jagalska E; Spahn M; Kruithof-de Julio M; Zoni E
BMC Cancer; 2019 Jun; 19(1):627. PubMed ID: 31238903
[TBL] [Abstract][Full Text] [Related]
13. Clinical, Cellular, and Molecular Evidence of the Additive Antitumor Effects of Biguanides and Statins in Prostate Cancer.
Jiménez-Vacas JM; Herrero-Aguayo V; Montero-Hidalgo AJ; Sáez-Martínez P; Gómez-Gómez E; León-González AJ; Fuentes-Fayos AC; Yubero-Serrano EM; Requena-Tapia MJ; López M; Castaño JP; Gahete MD; Luque RM
J Clin Endocrinol Metab; 2021 Jan; 106(2):e696-e710. PubMed ID: 33247590
[TBL] [Abstract][Full Text] [Related]
14. Krüppel-like factor 8 is a novel androgen receptor co-activator in human prostate cancer.
He HJ; Gu XF; Xu WH; Yang DJ; Wang XM; Su Y
Acta Pharmacol Sin; 2013 Feb; 34(2):282-8. PubMed ID: 23023312
[TBL] [Abstract][Full Text] [Related]
15. A Novel Splice Variant of the Inhibitor of Growth 3 Lacks the Plant Homeodomain and Regulates Epithelial-Mesenchymal Transition in Prostate Cancer Cells.
Melekhova A; Leeder M; Pungsrinont T; Schmäche T; Kallenbach J; Ehsani M; Mirzakhani K; Rasa SMM; Neri F; Baniahmad A
Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439818
[TBL] [Abstract][Full Text] [Related]
16. Foxm1 expression in prostate epithelial cells is essential for prostate carcinogenesis.
Cai Y; Balli D; Ustiyan V; Fulford L; Hiller A; Misetic V; Zhang Y; Paluch AM; Waltz SE; Kasper S; Kalin TV
J Biol Chem; 2013 Aug; 288(31):22527-41. PubMed ID: 23775078
[TBL] [Abstract][Full Text] [Related]
17. Dysregulation of RNA-Exosome machinery is directly linked to major cancer hallmarks in prostate cancer: Oncogenic role of PABPN1.
Sáez-Martínez P; Porcel-Pastrana F; Montero-Hidalgo AJ; Lozano de la Haba S; Sanchez-Sanchez R; González-Serrano T; Gómez-Gómez E; Martínez-Fuentes AJ; Jiménez-Vacas JM; Gahete MD; Luque RM
Cancer Lett; 2024 Mar; 584():216604. PubMed ID: 38244911
[TBL] [Abstract][Full Text] [Related]
18. P2X4 purinergic receptors offer a therapeutic target for aggressive prostate cancer.
Maynard JP; Lu J; Vidal I; Hicks J; Mummert L; Ali T; Kempski R; Carter AM; Sosa RY; Peiffer LB; Joshu CE; Lotan TL; De Marzo AM; Sfanos KS
J Pathol; 2022 Feb; 256(2):149-163. PubMed ID: 34652816
[TBL] [Abstract][Full Text] [Related]
19. SIRT7 depletion inhibits cell proliferation and androgen-induced autophagy by suppressing the AR signaling in prostate cancer.
Ding M; Jiang CY; Zhang Y; Zhao J; Han BM; Xia SJ
J Exp Clin Cancer Res; 2020 Feb; 39(1):28. PubMed ID: 32019578
[TBL] [Abstract][Full Text] [Related]
20. Host versus cell-dependent effects of β-arrestin 1 expression in prostate tumorigenesis.
Adekoya TO; Smith N; Thomas AJ; Lane TS; Burnette N; Rivers EJ; Li Y; Chen XL; Richardson RM
Carcinogenesis; 2021 May; 42(5):772-783. PubMed ID: 33710266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
